Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors

Ítems similars

• Assessment of EGFR Mutation Status in Lung Adenocarcinoma by Immunohistochemistry Using Antibodies Specific to the Two Major Forms of Mutant EGFR
  per: Brevet, Marie, et al.
  Publicat: (2010)
• Brief report: Screening for germline EGFR T790M mutations through lung cancer genotyping
  per: Oxnard, Geoffrey R., et al.
  Publicat: (2012)
• Uncommon EGFR mutations in lung adenocarcinoma: features and response to tyrosine kinase inhibitors
  per: Brindel, Aurélien, et al.
  Publicat: (2020)
• Detection of EGFR Mutations in the Plasma of Patients with Lung Adenocarcinoma for Real-Time Monitoring of Therapeutic Response to Tyrosine Kinase Inhibitors?
  per: Marcq, Marie, et al.
  Publicat: (2014)
• Association of KRAS and EGFR Mutations with Survival in Patients with Advanced Lung Adenocarcinomas
  per: Johnson, Melissa L., et al.
  Publicat: (2012)